LIVIVO - Search results -

Search results

Result 1 - 10 of total 38

Search options

Article ; Online: The incidental finding of elevated anti GQ1B antibodies in a patient with selective small fiber neuropathy.

Favoni, Valentina / Liguori, Rocco / Incensi, Alex / Fileccia, Enrico / Donadio, Vincenzo

2018 Volume 388, Page(s) 192–194

Abstract: Small fiber neuropathy (SFN) selectively affects small diameter sensory and/or autonomic axons. Pain and autonomic dysfunctions are the most common symptoms. SFN occurs in several autoimmune diseases and autoantibodies against neuronal proteins may play ... ...

Abstract	Small fiber neuropathy (SFN) selectively affects small diameter sensory and/or autonomic axons. Pain and autonomic dysfunctions are the most common symptoms. SFN occurs in several autoimmune diseases and autoantibodies against neuronal proteins may play a role in SFN pathophysiology. Anti-GQ1b antibody has been associated with Miller Fisher syndrome, Bickerstaff's brainstem encephalitis, acute ophthalmoplegia, pharyngeal-cervical-brachial weakness and peripheral neuropathy involving large fibers. Isolated SFN associated with anti-GQ1b antibodies has not been previously reported. Here we report a 45-year-old woman presenting with highly positive anti-GQ1b titer and selective SFN without central nervous system or peripheral large nerve involvement. She improved upon administration of adalizumab. Further studies will clarify a possible pathogenetic role of antiganglioside antibodies in SFN. Moreover, the recognition of antiganglioside antibodies in SFN may have therapeutic consequences with patients who would benefit from immunotherapy.
MeSH term(s)	Autoantibodies/metabolism ; Biomarkers/metabolism ; Female ; Gangliosides/immunology ; Humans ; Immunoglobulin M/metabolism ; Incidental Findings ; Middle Aged ; Small Fiber Neuropathy/diagnosis ; Small Fiber Neuropathy/drug therapy ; Small Fiber Neuropathy/immunology ; Small Fiber Neuropathy/pathology
Chemical Substances	Autoantibodies ; Biomarkers ; Gangliosides ; Immunoglobulin M ; GQ1b ganglioside (68652-37-9)
Language	English
Publishing date	2018-03-22
Publishing country	Netherlands
Document type	Case Reports ; Letter
ZDB-ID	80160-4
ISSN	1878-5883 ; 0022-510X ; 0374-8642
ISSN (online)	1878-5883
ISSN	0022-510X ; 0374-8642
DOI	10.1016/j.jns.2018.03.030
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 308: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Vessel-wall MRI in primary headaches: The role of neurogenic inflammation.

Merli, Elena / Rustici, Arianna / Gramegna, Laura Ludovica / Di Donato, Marco / Agati, Raffaele / Tonon, Caterina / Lodi, Raffaele / Favoni, Valentina / Pierangeli, Giulia / Cortelli, Pietro / Cevoli, Sabina / Cirillo, Luigi

Headache

2022 Volume 63, Issue 10, Page(s) 1372–1379

Abstract: Objective: The purpose of this study was to investigate if vessel-wall magnetic resonance imaging (VW-MRI) could differentiate among primary headaches disorders, such as migraine and cluster headache (CH), and detect the presence of neurogenic ... ...

Abstract	Objective: The purpose of this study was to investigate if vessel-wall magnetic resonance imaging (VW-MRI) could differentiate among primary headaches disorders, such as migraine and cluster headache (CH), and detect the presence of neurogenic inflammation. Background: The pathophysiology of primary headaches disorders is complex and not completely clarified. The activation of nociceptive trigeminal afferents through the release of vasoactive neuropeptides, termed "neurogenic inflammation," has been hypothesized. VW-MRI can identify vessel wall changes, reflecting the inflammatory remodeling of the vessel walls despite different etiologies. Methods: In this case series, we enrolled seven patients with migraine and eight patients with CH. They underwent a VW-MRI study before and after the intravenous administration of contrast medium, during and outside a migraine attack or cluster period. Two expert neuroradiologists analyzed the magnetic resonance imaging (MRI) studies to identify the presence of vessel wall enhancement or other vascular abnormalities. Results: Fourteen out of 15 patients had no enhancement. One out of 15, with migraine, showed a focal parietal enhancement in the intracranial portion of a vertebral artery, unmodified during and outside the attack, thus attributable to atherosclerosis. No contrast enhancement attributable to neurogenic inflammation was observed in VW-MRI, both during and outside the attack/cluster in all patients. Moreover, MRI angiography registered slight diffuse vasoconstriction in one of seven patients with migraine during the attack and in one of eight patients with cluster headache during the cluster period; both patients had taken triptans as symptomatic therapy for pain. Conclusions: These preliminary results suggest that VW-MRI studies are negative in patients with primary headache disorders even during migraine attacks or cluster periods. The VW-MRI studies did not detect signs of neurogenic inflammation in the intracranial intradural vessels of patients with migraine or CH.
MeSH term(s)	Humans ; Cluster Headache/diagnostic imaging ; Neurogenic Inflammation/diagnostic imaging ; Headache/diagnostic imaging ; Magnetic Resonance Imaging/methods ; Migraine Disorders
Language	English
Publishing date	2022-02-08
Publishing country	United States
Document type	Journal Article
ZDB-ID	410130-3
ISSN	1526-4610 ; 0017-8748
ISSN (online)	1526-4610
ISSN	0017-8748
DOI	10.1111/head.14253
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.B 539: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: P037. Headache in multiple sclerosis: prevalence and clinical features in a case control-study.

Terlizzi, Rossana / Merli, Elena / Buccellato, Elena / Giannini, Giulia / Favoni, Valentina / Pierangeli, Giulia / Salvi, Fabrizio / Cortelli, Pietro / Cevoli, Sabina

The journal of headache and pain

2017 Volume 16, Issue Suppl 1, Page(s) A83

Language	English
Publishing date	2017-01-26
Publishing country	England
Document type	Journal Article
ZDB-ID	2036768-5
ISSN	1129-2377 ; 1129-2369
ISSN (online)	1129-2377
ISSN	1129-2369
DOI	10.1186/1129-2377-16-S1-A83
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5464: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study.

Ornello, Raffaele / Baraldi, Carlo / Guerzoni, Simona / Lambru, Giorgio / Andreou, Anna P / Raffaelli, Bianca / Gendolla, Astrid / Barbanti, Piero / Aurilia, Cinzia / Egeo, Gabriella / Cevoli, Sabina / Favoni, Valentina / Vernieri, Fabrizio / Altamura, Claudia / Russo, Antonio / Silvestro, Marcello / Valle, Elisabetta Dalla / Mancioli, Andrea / Ranieri, Angelo /

Alfieri, Gennaro / Latysheva, Nina / Filatova, Elena / Talbot, Jamie / Cheng, Shuli / Holle, Dagny / Scheffler, Armin / Nežádal, Tomáš / Čtrnáctá, Dana / Šípková, Jitka / Matoušová, Zuzana / Casalena, Alfonsina / Maddestra, Maurizio / Viola, Stefano / Affaitati, Giannapia / Giamberardino, Maria Adele / Pistoia, Francesca / Reuter, Uwe / Sacco, Simona

The journal of headache and pain

2022 Volume 23, Issue 1, Page(s) 38

Abstract: Background: Monoclonal antibodies acting on the calcitonin gene-related peptide (CGRP) or its receptor have changed migraine preventive treatment. Those treatments have led to reconsidering the outcomes of migraine prevention. Available data mostly ... ...

Abstract	Background: Monoclonal antibodies acting on the calcitonin gene-related peptide (CGRP) or its receptor have changed migraine preventive treatment. Those treatments have led to reconsidering the outcomes of migraine prevention. Available data mostly considered benefits in terms of relative efficacy (percent or absolute decrease in monthly migraine days [MMDs] or headache days compared with baseline). However, not enough attention has been paid to residual MMDs and/or migraine-related disability in treated patients. In the present study, we aimed at comparing the relative and absolute efficacy of erenumab. Methods: ESTEEMen was a collaborative project among 16 European headache centers which already performed real-life data collections on patients treated with erenumab for at least 12 weeks. For the present study, we performed a subgroup analysis on patients with complete data on MMDs at baseline and at weeks 9-12 of treatment. Starting from efficacy thresholds proposed by previous literature, we classified patients into 0-29%, 30-49%, 50-74%, and ≥75% responders according to MMD decrease from baseline to weeks 9-12 of treatment. For each response category, we reported the median MMDs and Headache Impact test-6 (HIT-6) scores at baseline and at weeks 9-12. We categorized the number of residual MMDs at weeks 9-12 as follows: 0-3, 4-7, 8-14, ≥15. We classified HIT-6 score into four categories: ≤49, 50-55, 56-59, and ≥60. To keep in line with the original scope of the ESTEEMen study, calculations were performed in men and women. Results: Out of 1215 patients, at weeks 9-12, 381 (31.4%) had a 0-29% response, 186 (15.3%) a 30-49% response, 396 (32.6%) a 50-74% response, and 252 (20.7%) a ≥75% response; 246 patients (20.2%) had 0-3 residual MMDs, 443 (36.5%) had 4-7 MMDs, 299 (24.6%) had 8-14 MMDs, and 227 (18.7%) had ≥15 MMDs. Among patients with 50-74% response, 246 (62.1%) had 4-7 and 94 (23.7%) 8-14 residual MMDs, while among patients with ≥75% response 187 (74.2%) had 0-3 and 65 (25.8%) had 4-7 residual MMDs. Conclusions: The present study shows that even patients with good relative response to erenumab may have a clinically non-negligible residual migraine burden. Relative measures of efficacy cannot be enough to thoroughly consider the efficacy of migraine prevention.
MeSH term(s)	Antibodies, Monoclonal, Humanized/therapeutic use ; Calcitonin Gene-Related Peptide ; Calcitonin Gene-Related Peptide Receptor Antagonists/pharmacology ; Calcitonin Gene-Related Peptide Receptor Antagonists/therapeutic use ; Female ; Humans ; Male ; Migraine Disorders/drug therapy ; Migraine Disorders/prevention & control
Chemical Substances	Antibodies, Monoclonal, Humanized ; Calcitonin Gene-Related Peptide Receptor Antagonists ; erenumab (I5I8VB78VT) ; Calcitonin Gene-Related Peptide (JHB2QIZ69Z)
Language	English
Publishing date	2022-03-19
Publishing country	England
Document type	Comparative Study ; Journal Article
ZDB-ID	2036768-5
ISSN	1129-2377 ; 1129-2369
ISSN (online)	1129-2377
ISSN	1129-2369
DOI	10.1186/s10194-022-01408-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5464: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies.

Thellung, Stefano / Favoni, Roberto E / Würth, Roberto / Nizzari, Mario / Pattarozzi, Alessandra / Daga, Antonio / Florio, Tullio / Barbieri, Federica

Current drug targets

2015 Volume 17, Issue 7, Page(s) 824–849

Abstract: Malignant pleural mesothelioma (MPM) is one of the deadliest and most heterogeneous tumors, highly refractory to multimodal therapeutic approach, including surgery, chemo- and radiotherapy. Preclinical and clinical studies exploring the efficacy of drugs ...

Abstract	Malignant pleural mesothelioma (MPM) is one of the deadliest and most heterogeneous tumors, highly refractory to multimodal therapeutic approach, including surgery, chemo- and radiotherapy. Preclinical and clinical studies exploring the efficacy of drugs targeting tyrosine kinases, angiogenesis and histone deacetylases, did not fulfil the expected clinical benefits. Thus, novel molecular targets should be identified from a definite knowledge of the unique biology and most relevant transduction pathways of MPM cells. Cancer stem cells (CSCs) are a subset of malignant precursors responsible for initiation, progression, resistance to cytotoxic drugs, recurrence and metastatic diffusion of tumor cells. CSCs are putative driving factors for MPM development and contribute to its clinical and biological heterogeneity; hence, targeted eradication of CSCs represents an ineludible goal to counteract MPM aggressiveness. In this context, innovative preclinical models could be exploited to identify novel intracellular pathway inhibitors able to target CSC viability. Novel drug targets have been identified among key factors responsible for the oncogenic transformation of mesothelial cells, often directly induced by asbestos. These include mitogenic and anti-apoptotic signaling that may also be activated by autocrine and paracrine cytokine pathways controlling cell plasticity. Both signaling pathways affecting proto-oncogene and transcription factor expression, or genetic and epigenetic alterations, such as mutations in cell cycle genes and silencing of tumor suppressor genes, represent promising disease-specific targets. In this review we describe current knowledge of MPM cell biology, focusing on potential targets to be tested in pharmacological studies, and highlighting results and challenges of clinical translation.
MeSH term(s)	Animals ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Clinical Trials as Topic ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Mesothelioma/drug therapy ; Mesothelioma/pathology ; Mesothelioma, Malignant ; Molecular Targeted Therapy ; Neoplastic Stem Cells/drug effects ; Neoplastic Stem Cells/pathology ; Pleural Neoplasms/drug therapy ; Pleural Neoplasms/pathology ; Signal Transduction/drug effects
Chemical Substances	Antineoplastic Agents
Language	English
Publishing date	2015-07-27
Publishing country	United Arab Emirates
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2064859-5
ISSN	1873-5592 ; 1389-4501
ISSN (online)	1873-5592
ISSN	1389-4501
DOI	10.2174/1389450116666150804110714
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5578: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.

Pattarozzi, Alessandra / Carra, Elisa / Favoni, Roberto E / Würth, Roberto / Marubbi, Daniela / Filiberti, Rosa Angela / Mutti, Luciano / Florio, Tullio / Barbieri, Federica / Daga, Antonio

Stem cell research & therapy

2017 Volume 8, Issue 1, Page(s) 119

Abstract: Background: Malignant pleural mesothelioma is an aggressive cancer, characterized by rapid progression and high mortality. Persistence of tumor-initiating cells (TICs, or cancer stem cells) after cytotoxic drug treatment is responsible for tumor relapse, ...

Abstract	Background: Malignant pleural mesothelioma is an aggressive cancer, characterized by rapid progression and high mortality. Persistence of tumor-initiating cells (TICs, or cancer stem cells) after cytotoxic drug treatment is responsible for tumor relapse, and represents one of the main reasons for the poor prognosis of mesothelioma. In fact, identification of the molecules affecting TIC viability is still a significant challenge. Methods: TIC-enriched cultures were obtained from 10 human malignant pleural mesotheliomas and cultured in vitro. Three fully characterized tumorigenic cultures, named MM1, MM3, and MM4, were selected and used to assess antiproliferative effects of the multi-kinase inhibitor sorafenib. Cell viability was investigated by MTT assay, and cell cycle analysis as well as induction of apoptosis were determined by flow cytometry. Western blotting was performed to reveal the modulation of protein expression and the phosphorylation status of pathways associated with sorafenib treatment. Results: We analyzed the molecular mechanisms of the antiproliferative effects of sorafenib in mesothelioma TIC cultures. Sorafenib inhibited cell cycle progression in all cultures, but only in MM3 and MM4 cells was this effect associated with Mcl-1-dependent apoptosis. To investigate the mechanisms of sorafenib-mediated antiproliferative activity, TICs were treated with epidermal growth factor (EGF) or basic fibroblast growth factor (bFGF) causing, in MM3 and MM4 cells, MEK, ERK1/2, Akt, and STAT3 phosphorylation. These effects were abolished by sorafenib only in bFGF-treated cells, while a modest inhibition occurred after EGF stimulation, suggesting that sorafenib effects are mainly due to FGF receptor (FGFR) inhibition. Indeed, FGFR1 phosphorylation was inhibited by sorafenib. Moreover, in MM1 cells, which release high levels of bFGF and showed autocrine activation of FGFR1 and constitutive phosphorylation/activation of MEK-ERK1/2, sorafenib induced a more effective antiproliferative response, confirming that the main target of the drug is the inhibition of FGFR1 activity. Conclusions: These results suggest that, in malignant pleural mesothelioma TICs, bFGF signaling is the main target of the antiproliferative response of sorafenib, acting directly on the FGFR1 activation. Patients with constitutive FGFR1 activation via an autocrine loop may be more sensitive to sorafenib treatment and the analysis of this possibility warrants further clinical investigation.
MeSH term(s)	Animals ; Apoptosis/drug effects ; Cell Cycle Checkpoints/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Separation ; Cell Survival/drug effects ; Down-Regulation/drug effects ; Epidermal Growth Factor/pharmacology ; ErbB Receptors/metabolism ; Fibroblast Growth Factor 2/pharmacology ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Mesothelioma/drug therapy ; Mesothelioma/metabolism ; Mesothelioma/pathology ; Mesothelioma, Malignant ; Mice, Inbred NOD ; Mice, SCID ; Models, Biological ; Myeloid Cell Leukemia Sequence 1 Protein/metabolism ; Neoplastic Stem Cells/drug effects ; Neoplastic Stem Cells/metabolism ; Neoplastic Stem Cells/pathology ; Niacinamide/analogs & derivatives ; Niacinamide/pharmacology ; Niacinamide/therapeutic use ; Phenylurea Compounds/pharmacology ; Phenylurea Compounds/therapeutic use ; Pleural Neoplasms/drug therapy ; Pleural Neoplasms/metabolism ; Pleural Neoplasms/pathology ; Receptor, Fibroblast Growth Factor, Type 1/antagonists & inhibitors ; Receptor, Fibroblast Growth Factor, Type 1/metabolism ; Signal Transduction/drug effects ; Sorafenib ; Time Factors
Chemical Substances	MCL1 protein, human ; Myeloid Cell Leukemia Sequence 1 Protein ; Phenylurea Compounds ; Fibroblast Growth Factor 2 (103107-01-3) ; Niacinamide (25X51I8RD4) ; Epidermal Growth Factor (62229-50-9) ; Sorafenib (9ZOQ3TZI87) ; ErbB Receptors (EC 2.7.10.1) ; FGFR1 protein, human (EC 2.7.10.1) ; Receptor, Fibroblast Growth Factor, Type 1 (EC 2.7.10.1)
Language	English
Publishing date	2017-05-25
Publishing country	England
Document type	Journal Article
ZDB-ID	2548671-8
ISSN	1757-6512 ; 1757-6512
ISSN (online)	1757-6512
ISSN	1757-6512
DOI	10.1186/s13287-017-0573-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Treatment of withdrawal headache in patients with medication overuse headache: a pilot study.

Cevoli, Sabina / Giannini, Giulia / Favoni, Valentina / Terlizzi, Rossana / Sancisi, Elisa / Nicodemo, Marianna / Zanigni, Stefano / Bacchi Reggiani, Maria Letizia / Pierangeli, Giulia / Cortelli, Pietro

The journal of headache and pain

2017 Volume 18, Issue 1, Page(s) 56

Abstract: Background: Drug withdrawal still remains the key element in the treatment of Medication Overuse Headache (MOH), but there is no consensus about the withdrawal procedure. Still debated is the role of the steroid therapy. The aim of this study was to ... ...

Abstract	Background: Drug withdrawal still remains the key element in the treatment of Medication Overuse Headache (MOH), but there is no consensus about the withdrawal procedure. Still debated is the role of the steroid therapy. The aim of this study was to evaluate the effectiveness of methylprednisolone or paracetamol in the treatment of withdrawal headache in MOH. Methods: We performed a pilot, randomized, single-blinded, placebo controlled trial. MOH patients, unresponsive to a 3 months prophylaxis, underwent withdrawal therapy on an inpatient basis. Overused medications were abruptly stopped and methylprednisolone 500 mg i.v (A) or paracetamol 4 g i.v. (B) or placebo i.v. (C) were given daily for 5 days. Patients were monitored at 1 and 3 months. Results: Eighty three consecutive MOH patients were enrolled. Fifty seven patients completed the study protocol. Nineteen patients were randomized to each group. Withdrawal headache on the 5th day was absent in 21.0% of group A, in 31.6% of group B and in 12.5% of group C without significant differences. Withdrawal headache intensity decreased significantly after withdrawal without differences among the groups. Rregardless of withdrawal treatment, 52% MOH patients reverted to an episodic migraine and 62% had no more medication overuse after 3 months. Conclusions: This study suggests that in a population of severe MOH patients, withdrawal headache decreased significantly in the first 5 days of withdrawal regardless of the treatment used. Methylprednisolone and paracetamol are not superior to placebo at the end of the detoxification program.
MeSH term(s)	Acetaminophen/therapeutic use ; Adult ; Analgesics, Non-Narcotic/therapeutic use ; Drug Therapy, Combination ; Female ; Glucocorticoids/therapeutic use ; Headache Disorders, Secondary/drug therapy ; Humans ; Intention to Treat Analysis ; Male ; Methylprednisolone/therapeutic use ; Middle Aged ; Migraine Disorders/drug therapy ; Pilot Projects ; Prescription Drug Overuse ; Single-Blind Method ; Substance Withdrawal Syndrome/drug therapy ; Treatment Outcome
Chemical Substances	Analgesics, Non-Narcotic ; Glucocorticoids ; Acetaminophen (362O9ITL9D) ; Methylprednisolone (X4W7ZR7023)
Language	English
Publishing date	2017-05-12
Publishing country	England
Document type	Journal Article ; Randomized Controlled Trial
ZDB-ID	2036768-5
ISSN	1129-2377 ; 1129-2369
ISSN (online)	1129-2377
ISSN	1129-2369
DOI	10.1186/s10194-017-0763-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5464: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in Men.

Ornello, Raffaele / Baraldi, Carlo / Guerzoni, Simona / Lambru, Giorgio / Fuccaro, Matteo / Raffaelli, Bianca / Gendolla, Astrid / Barbanti, Piero / Aurilia, Cinzia / Cevoli, Sabina / Favoni, Valentina / Vernieri, Fabrizio / Altamura, Claudia / Russo, Antonio / Silvestro, Marcello / Dalla Valle, Elisabetta / Mancioli, Andrea / Ranieri, Angelo / Alfieri, Gennaro /

Latysheva, Nina / Filatova, Elena / Talbot, Jamie / Cheng, Shuli / Holle, Dagny / Scheffler, Armin / Nežádal, Tomáš / Čtrnáctá, Dana / Šípková, Jitka / Matoušová, Zuzana / Sette, Lucia / Casalena, Alfonsina / Maddestra, Maurizio / Viola, Stefano / Affaitati, Giannapia / Giamberardino, Maria Adele / Pistoia, Francesca / Reuter, Uwe / Sacco, Simona

Frontiers in neurology

2021 Volume 12, Page(s) 774341

Abstract: Objective: ...

Abstract	Objective:
Language	English
Publishing date	2021-12-16
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2564214-5
ISSN	1664-2295
ISSN	1664-2295
DOI	10.3389/fneur.2021.774341
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach.

Favoni, R E / de Cupis, A

Pharmacological reviews

2000 Volume 52, Issue 2, Page(s) 179–206

Abstract: The processes of cellular proliferation and progressive acquisition of a specialized phenotype show a high degree of coordination. In particular, these complex signaling networks mediating cell growth, differentiation, migration, and apoptosis are ... ...

Abstract	The processes of cellular proliferation and progressive acquisition of a specialized phenotype show a high degree of coordination. In particular, these complex signaling networks mediating cell growth, differentiation, migration, and apoptosis are regulated in part by polypeptide growth factors that can act, by autocrine and/or paracrine mechanisms of action, as positive or negative modulators. Because these growth factors are unable to cross the hydrophobic cell membrane, they exert their effects via binding to cell surface receptors, most of which possess intrinsic tyrosine kinase activity. Owing to the interaction of polypeptide growth factors with their specific transmembrane receptors, a cascade of intracellular biochemical signals, resulting in the activation and repression of various subsets of genes, is triggered. One of the major incentives for studying factors that regulate processes of proliferation and differentiation is the recognition of their involvement in tumorigenesis. Genetic aberrations in growth factors signaling pathways are, in fact, inextricably linked to cancer. Malignant cells arise as a result of a stepwise progression of genetic events characterized by the unregulated expression of growth factors or components of their signaling networks. The main aim of this review is to examine the current understanding of the crucial contribution that several growth factors may have on transformation, tumorigenesis, and progression in several human tumors among the most widespread in western countries. For this purpose, we will analyze the chemistry and the molecular organization of the most important growth factors and their specific receptors. In addition, we will focus on the mechanisms of signal transduction, the complex cascade of biochemical events ensued from the growth factor/receptor binding. The present knowledge of the role of growth factor biochemical signaling networks in cancer leads to improvements not only in diagnosis and prognosis for this disease, but also for new and more targeted therapeutic intervention. The second part of this review will focus on the novel pharmacological approaches for cancer therapy that have been developed already or are being developed with the aim to specifically interfere at various steps of the growth factors signaling pathways.
MeSH term(s)	Animals ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Growth Substances/physiology ; Humans ; Neoplasms/drug therapy ; Neoplasms/physiopathology ; Neoplasms, Experimental/drug therapy ; Neoplasms, Experimental/physiopathology ; Peptides/physiology ; Receptors, Growth Factor/drug effects ; Signal Transduction/drug effects ; Signal Transduction/physiology
Chemical Substances	Antineoplastic Agents ; Growth Substances ; Peptides ; Receptors, Growth Factor
Language	English
Publishing date	2000-06
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	209898-2
ISSN	1521-0081 ; 0031-6997
ISSN (online)	1521-0081
ISSN	0031-6997
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uf I Zs.148: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: New vs old fashioned oestradiol antagonists in mammary carcinoma: 'in vitro' and 'in vivo' pharmacological approaches.

de Cupis, A / Schettini, G / Favoni, R E

Pharmacological research

1999 Volume 39, Issue 5, Page(s) 335–344

Abstract: The rationale underlying therapeutic strategies designed to inhibit the action of endogenous sex hormones in malignant breast cells is provided by the demonstration of their involvement in supporting the development and growth of breast carcinoma. The ... ...

Abstract	The rationale underlying therapeutic strategies designed to inhibit the action of endogenous sex hormones in malignant breast cells is provided by the demonstration of their involvement in supporting the development and growth of breast carcinoma. The surgical removal of steroid-secreting glands, in order to reduce the level of oestrogens reaching their target tissues, has for years been substituted by the so-called endocrinotherapeutic approach, which is based on the counteraction of the steroid hormone activity by the hormonal receptor blockade with suitable antioestrogenic compounds. Over the past 25 years, the non-steroidal oestrogen antagonist tamoxifen has become the standard endocrine treatment for breast cancer. The triphenylethylene-derivative compound competes efficiently for binding to the oestrogen receptor, but the complex retains some transcriptional activity. Consequently, tamoxifen exhibits, both ' in vitro and in vivo ', a range of biological activity from full oestrogen antagonism to partial agonism. There is also evidence suggesting that the agonist activity of this compound may ultimately stimulate breast tumour growth, thus causing some treatment failures. Moreover, the use of tamoxifen is limited by the possible onset of drug-resistance in many patients. Nevertheless, widely tested tamoxifen has proved to be very helpful for the development of new compounds to be used as long-term adjuvant therapy or as preventive agents. These novel oestrogen antagonists belong to two major classes: tamoxifen analogs and new pure steroidal-like antioestrogens. The search for and development of compounds devoid of tamoxifen cross-resistance, with a safer toxicity profile as well as the lack of oestrogenic effects, provide the bases to improve the current therapeutic applications of antioestrogens.
MeSH term(s)	Animals ; Antineoplastic Agents, Hormonal/pharmacology ; Antineoplastic Agents, Hormonal/therapeutic use ; Breast Neoplasms/drug therapy ; Breast Neoplasms/prevention & control ; Clinical Trials as Topic ; Estrogen Antagonists/pharmacology ; Estrogen Antagonists/therapeutic use ; Female ; Humans ; Receptors, Estrogen/agonists ; Receptors, Estrogen/antagonists & inhibitors ; Tamoxifen/pharmacology ; Tamoxifen/therapeutic use
Chemical Substances	Antineoplastic Agents, Hormonal ; Estrogen Antagonists ; Receptors, Estrogen ; Tamoxifen (094ZI81Y45)
Language	English
Publishing date	1999-05
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	1003347-6
ISSN	1096-1186 ; 1043-6618 ; 0031-6989
ISSN (online)	1096-1186
ISSN	1043-6618 ; 0031-6989
DOI	10.1006/phrs.1998.0437
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 721: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito